Medindia

X

Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS

Wednesday, April 23, 2008 General News J E 4
Advertisement
STOCKHOLM, April 22

- Summary: Using Protein Tomography(TM), Sidec Investigated inCollaboration With Genmab the Molecular Mode of Action of Humax- EGFr(Zalutumumab). In This Study Sidec Showed That EGFr is Flexible and ThatZalutumumab Locks the EGFr Into a Very Compact Inactive Conformation TherebyInhibiting Cell Signaling and Cancer Cell Growth.

Sidec AB announced today that together with Genmab the molecular mode ofaction of HuMax-EGFr (zalutumumab) has been determined. It was shown thatzalutumumab locks the epidermal growth factor receptor (EGFr) molecules intoa compact, inactive conformation. Flexibility is crucial to the role of theEGFr in signaling, and this study, done with Sidec's proprietary methodologyProtein Tomography(TM), has played a central role in the understanding of theinhibition of individual EGFr molecules. Moreover, Sidec's unique technologyconfirmed that HuMax-EGFr binds bivalently to the EGFr. Prevention of thereceptor dimerization as well as locking the EGFr molecules in the inactiveform both contribute to the inhibition of signaling and cancer cell growth.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )

This data will be demonstrated on Sidec's First Protein TomographySymposium at the fourth annual PEGS Summit 28 April - 2 May at theIntercontinental Hotel in Boston.

With Protein Tomography it is possible to study the molecular mode ofaction of individual molecules in situ and in vitro. The unique biologicalinformation obtained can also be used to prioritize the most promisingmonoclonal antibodies/projects and to locate the antibody binding epitope.

"These results clearly show the importance of understanding the molecularmode of action and to capture the flexibility of a receptor when developingtherapeutic antibodies. Today this can only be done with ProteinTomography(TM) and we are proud to have contributed to Genmab's new insightto HuMax-EGFr mechanism of action." says Hans Johansson CEO at Sidec AB.

The new findings will be published in the journal Proceedings of theNational Academy of Science of the United States of America (PNAS) in theedition published on April 21, 2008

About Sidec

Sidec studies molecular interactions in situ and in vitro using itsproprietary technology Protein Tomography(TM). Sidec AB offers collaborationresearch projects to the biopharmaceutical industry and reveals uniqueinformation to prioritize the most promising therapeutic antibody and tolocate the antibody binding epitope.For more information, please contact: Mr.Hans Johansson, CEO Phone: +46(0)8-4777-602 http://www.sidec.com

SOURCE Sidec AB
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
DuPont Reports First Quarter Earnings Growth of Ov...
S
New: Longevinex(R) First to Introduce Micronized R...